GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Energenesis Biomedical Co Ltd (TPE:6657) » Definitions » Quick Ratio

Energenesis Biomedical Co (TPE:6657) Quick Ratio : 27.49 (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Energenesis Biomedical Co Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Energenesis Biomedical Co's quick ratio for the quarter that ended in Mar. 2025 was 27.49.

Energenesis Biomedical Co has a quick ratio of 27.49. It generally indicates good short-term financial strength.

The historical rank and industry rank for Energenesis Biomedical Co's Quick Ratio or its related term are showing as below:

TPE:6657' s Quick Ratio Range Over the Past 10 Years
Min: 8.14   Med: 24.3   Max: 45.91
Current: 27.49

During the past 10 years, Energenesis Biomedical Co's highest Quick Ratio was 45.91. The lowest was 8.14. And the median was 24.30.

TPE:6657's Quick Ratio is ranked better than
95.52% of 1495 companies
in the Biotechnology industry
Industry Median: 3.38 vs TPE:6657: 27.49

Energenesis Biomedical Co Quick Ratio Historical Data

The historical data trend for Energenesis Biomedical Co's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Energenesis Biomedical Co Quick Ratio Chart

Energenesis Biomedical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.30 27.14 20.64 33.67 19.17

Energenesis Biomedical Co Quarterly Data
Jun19 Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.08 26.74 21.06 19.17 27.49

Competitive Comparison of Energenesis Biomedical Co's Quick Ratio

For the Biotechnology subindustry, Energenesis Biomedical Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Energenesis Biomedical Co's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Energenesis Biomedical Co's Quick Ratio falls into.


;
;

Energenesis Biomedical Co Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Energenesis Biomedical Co's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Quick Ratio (A: Dec. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(687.746-0.75)/35.832
=19.17

Energenesis Biomedical Co's Quick Ratio for the quarter that ended in Mar. 2025 is calculated as

Quick Ratio (Q: Mar. 2025 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(1030.916-0.892)/37.464
=27.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Energenesis Biomedical Co  (TPE:6657) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Energenesis Biomedical Co Quick Ratio Related Terms

Thank you for viewing the detailed overview of Energenesis Biomedical Co's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Energenesis Biomedical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 21, Lane 583, Ruiguang Road, 6th Floor -3, Neihu District, Taipei, TWN, 11492
Energenesis Biomedical Co Ltd is a biomedicine company. It is engaged in businesses related to biological experimentation and analysis, as well as new drug development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. Its product pipeline consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream, among others.

Energenesis Biomedical Co Headlines

No Headlines